The invention provides a new technology of immune tolerance. In detail, the present invention finds for the first time that a cell preparation containing cells that inhibit the interaction of CD80 / CD86 and CD28 to induce disability is administered to an organ transplant patient (recipient) to induce immune tolerance Even if the cells from the cell preparation disappear from the recipient, the immune tolerance persists (infectious immune tolerance). It was further confirmed that such cell preparations can induce immune tolerance to allergies or immune rejection reactions generated by cells, tissues or organs such as iPS cells or the like.本發明提供一種免疫耐受之新技術。詳細而言，本發明首次發現：將包含經抑制CD80/CD86與CD28之相互作用之抑制因子誘導失能之細胞的細胞製劑投予至器官移植患者(接受者)而誘導免疫耐受之技術中，即便來自細胞製劑之細胞自接受者消失，免疫耐受亦持續(感染性免疫耐受)。進而證實，此種細胞製劑可誘發對過敏或由iPS細胞等或來自該等之細胞、組織或器官產生之免疫排斥反應之免疫耐受。
